High Sensitivity CRP Predicts Long-Term Mortality in Patients with Atrial Fibrillation and Evident Acute Coronary Syndrome

DOI: 10.4236/ijcm.2013.43025   PDF   HTML   XML   3,159 Downloads   4,817 Views   Citations


Background: Atrial fibrillation (AF) is a frequent arrhythmia associated with an adverse prognostic value in patients with ACS. Risk stratification as well as diagnosis of ACS is strongly supported by biomarkers. High sensitivity CRP (hs-CRP) is known to be elevated in patients presenting with ACS as well as with AF.Methods: In total, 2034 consecutive patients with an ACS were analysed. The incidence of AF in the setting of ACS, the prognostic value of hs-CRP and the clinical outcome within 6 months were subject of the study. Death after 6 months was considered as primary endpoint. Results: The frequency of AF among patients admitted with suspected ACS was 124 (6.1%). During 6-month follow-up the mortality rate among patients with AF was significantly higher (20 [16.1%] vs 133 [6.9%]; log-rank 13.72; p < 0.001) compared to patients without AF. Cox regression analysis revealed an increased risk for ACS patients with AF with an adjusted HR of 2.63 (95% CI 1.48 - 3.78; p < 0.001). Patients with AF showed significant higher levels of hs-CRP than patients without AF (6.01mg/dl IQR [1.7 - 17.8] vs 3.3mg/dl IQR [1.37 - 9.83]; p = 0.003). By the use of multivariate Cox regression analysis, risk of mortality was higher when AF patients had higher concentrations of hs-CRP (HR 1.076; 95% CI 1.02 - 1.13; p = 0.002).Conclusions: AF is a strong and independent indicator for increased mortality in patients presenting with ACS. hs-CRP predicts mortality in AF patients and should be considered for risk stratification in clinical routine.

Share and Cite:

C. Liebetrau, L. Gaede, S. Szardien, J. Rixe, O. Doerr, M. Willmer, M. Weber, A. Rolf, H. Möllmann, A. Elsässer, C. Hamm and H. Nef, "High Sensitivity CRP Predicts Long-Term Mortality in Patients with Atrial Fibrillation and Evident Acute Coronary Syndrome," International Journal of Clinical Medicine, Vol. 4 No. 3, 2013, pp. 137-144. doi: 10.4236/ijcm.2013.43025.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. S. Tsang, Y. Miyasaka, M. E. Barnes, et al., “Epidemiological Profile of Atrial Fibrillation: A Contemporary Perspective,” Progress in Cardiovascular Diseases, Vol. 48, No. 1, 2005, pp. 1-8. doi:10.1016/j.pcad.2005.06.001
[2] E. J. Benjamin, P. A. Wolf, R. B. D’Agostino, et al., “Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study,” Circulation, Vol. 98, 1998, pp. 946-952. doi:10.1161/01.CIR.98.10.946
[3] A. Cameron, M. J. Schwartz, R. A. Kronmal, et al., “Prevalence and Significance of Atrial Fibrillation in Coronary Artery Disease (CASS Registry),” American Journal of Cardiology, Vol. 61, No. 10, 1988, pp. 714-717. doi:10.1016/0002-9149(88)91053-3
[4] N. R. Desai and R. P. Giugliano, “Can We Predict Outcomes in Atrial Fibrillation?” Clinical Cardiology, Vol. 35, Suppl. 1, 2012, pp. 10-14. doi:10.1002/clc.20989
[5] R. D. Lopes, K. S. Pieper, J. R. Horton, et al., “Short-and Long-Term Outcomes Following Atrial Fibrillation in Patients with Acute Coronary Syndromes with or without ST-Segment Elevation,” Heart, Vol. 94, No. 7, 2008, pp. 867-873. doi:10.1136/hrt.2007.134486
[6] J. Schmitt, G. Duray, B. J. Gersh, et al., “Atrial Fibrillation in Acute Myocardial Infarction: A Systematic Review of the Incidence. Clinical Features and Prognostic Implications,” European Heart Journal, Vol. 30, No. 9, 2009, pp. 1038-1045. doi:10.1093/eurheartj/ehn579
[7] R. H. Mehta, O. H. Dabbous, C. B. Granger, et al. (For the GRACE Investigators), “Comparison of Outcomes of Patients with Acute Coronary Syndromes with and without Atrial Fibrillation,” American Journal of Cardiology, Vol. 92, No. 9, 2003, pp. 1031-1036. doi:10.1016/j.amjcard.2003.06.001
[8] S. S. Rathore, A. K. Berger, K. P. Weinfurt, et al., “Acute Myocardial Infarction Complicated by Atrial Fibrillation in the Elderly: Prevalence and Outcomes,” Circulation, Vol. 101, 2000, pp. 969-974. doi:10.1161/01.CIR.101.9.969
[9] D. Poci, M. Hartford, T. Karlsson, et al., “Effect of New Versus Known versus No Atrial Fibrillation on 30-Day and 10-Year Mortality in Patients with Acute Coronary Syndrome,” American Journal of Cardiology, Vol. 110, No. 2, 2012, pp. 217-221.
[10] P. Jabre, X. Jouven, F. Adnet, G. Thabut, S. J. Bielinski, S. A. Weston and V. L. Roger, “Atrial Fibrillation and Death after Myocardial Infarction: A Community Study,” Circulation, Vol. 123, No. 19, 2011, pp. 2094-2100. doi:10.1161/CIRCULATIONAHA.110.990192
[11] R. F. Alcock, A. S. Yong, A. C. Ng, et al., “Acute Coronary Syndrome and Stable Coronary Artery Disease: Are They So Different? Long-Term Outcomes in a Contemporary PCI Cohort,” International Journal of Cardiology, 2012. doi:10.1016/j.ijcard.2012.04.011
[12] C. Heeschen, S. Dimmeler, C. W. Hamm, et al., “CAPTURE Study Investigators. Pregnancy-Associated Plasma Protein-A Levels in Patients with Acute Coronary Syndromes: Comparison with Markers of Systemic Inflammation, Platelet Activation, and Myocardial Necrosis,” Journal of the American College of Cardiology, Vol. 45, No. 2, 2005, pp. 229-237. doi:10.1016/j.jacc.2004.09.060
[13] S. Q. Khan, O. S. Dhillon, R. J. O’Brien, et al., “C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study,” Circulation, Vol. 115, 2007, pp. 2103-2110. doi:10.1161/CIRCULATIONAHA.106.685503
[14] M. Weber, O. Bazzino, J. L. Navarro Estrada, et al., “Improved Diagnostic and Prognostic Performance of a New High-Sensitive Troponin T Assay in Patients with Acute Coronary Syndrome,” American Heart Journal, Vol. 162, No. 1, 2011, pp. 81-88. doi:10.1016/j.ahj.2011.04.007
[15] S. A. Kim, S. J. Rhee, C. Y. Shim, et al., “Prognostic Value of N-Terminal Probrain Natriuretic Peptide Level on Admission in Patients with Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction,” Coronary Artery Disease, Vol. 22, No. 3, 2011, pp. 153- 157. doi:10.1097/MCA.0b013e3283423622
[16] M. Hartford, O. Wiklund, L. Mattsson-Hulten, et al., “C-Reactive Protein, Interleukin-6, Secretory Phospholipase A2 Group IIA and Intercellular Adhesion Molecule-1 in the Prediction of Late Outcome Events after Acute Coronary Syndromes,” Journal of Internal Medicine, Vol. 262, No. 5, 2007, pp. 526-536.
[17] M. N. Zairis, E. N. Adamopoulou, S. J. Manousakis, et al. (Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators), “The Impact of hs C-Reactive Protein and Other Inflammatory Biomarkers on Long-Term Cardiovascular Mortality in Patients with Acute Coronary Syndromes,” Atherosclerosis, Vol. 194, No. 2, 2007, pp. 397-402. doi:10.1016/j.atherosclerosis.2006.08.008
[18] B. Lindahl, H. Toss, A. Siegbahn, P. Venge and L. Wallentin, “Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery Disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease,” New England Journal of Medicine, Vol. 343, 2000, pp. 1139-1147. doi:10.1056/NEJM200010193431602
[19] C. Mueller, H. J. Buettner, J. M. Hodgson, et al., “Inflammationandlong-Term Mortality after Non-ST-Elevation Acute Coronary Syndrome Treated with a Very Early Invasive Strategy in 1042 Consecutive Patients,” Circulation, Vol. 105, 2002, pp. 1412-1415. doi:10.1161/01.CIR.0000012625.02748.62
[20] F. Haverkate, S. G. Thompson, S. D. M. Pyke, J. R. Gallimore and M. B. Pepys, “Production of C-Reactive Protein and Risk of Coronary Events in Stable and Unstable Angina,” Lancet, Vol. 349, No. 9050, 1997, pp. 462-466. doi:10.1016/S0140-6736(96)07591-5
[21] P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy and C. H. Hennekens, “Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men,” New England Journal of Medicine, Vol. 336, 1997, pp. 973-979. doi:10.1056/NEJM199704033361401
[22] W. Koenig, M. Sund, M. Frohlich, H. G. Fischer, H. Lowel, A. Doring, et al., “C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middleaged Men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992,” Circulation, Vol. 99, 1999, pp. 237-242. doi:10.1161/01.CIR.99.2.237
[23] R. Rückerl, A. Peters, N. Khuseyinova, et al., “Determinants of the Acute-Phase Protein C-Reactive Protein in Myocardial Infarction Survivors: The Role of Comorbidities and Environmental Factors,” Clinical Chemistry, Vol. 55, No. 2, 2009, pp. 322-335.
[24] T. Sano, A. Tanaka, M. Namba, et al., “C-Reactive Protein and Lesion Morphology in Patients with Acute Myocardial Infarction,” Circulation, Vol. 108, 2003, pp. 282-285. doi:10.1161/01.CIR.0000079173.84669.4F
[25] H. Otake, J. Shite, T. Shinke, et al., “Relation between Plasma Adiponectin, High-Sensitivity C-Reactive Protein, and Coronary Plaque Components in Patients with Acute Coronary Syndrome,” American Journal of Cardiology, Vol. 101, No. 1, 2008, pp. 1-7. doi:10.1016/j.amjcard.2007.07.041
[26] M. K. Chung, D. O. Martin, D. Sprecher, et al., “C- Reactive Protein Elevation in Patients with Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation,” Circulation, Vol. 104, 2001, pp. 2886-2891. doi:10.1161/hc4901.101760
[27] E. Hatzinikolaou-Kotsakou, D. Tziakas, A. Hotidis, et al., “Relation of C-Reactive Protein to the First Onset and the Recurrence Rate in Lone Atrial Fibrillation,” American Journal of Cardiology, Vol. 97, No. 5, 2006, pp. 659-661. doi:10.1016/j.amjcard.2005.09.104
[28] J. Hermida, F. L. Lopez, R. Montes, et al., “Usefulness of High-Sensitivity C-Reactive Protein to Predict Mortality in Patients with Atrial Fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study),” American Journal of Cardiology, Vol. 109, No. 1, 2012, pp. 95-99. doi:10.1016/j.amjcard.2011.08.010
[29] J. J. McMurray, S. Adamopoulos, S. D. Anker, et al., “ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC,” European Heart Journal, Vol. 33, No. 14, 2012, pp. 1787-1874.
[30] D. H. Lau, L. T. Huynh, D. P. Chew, et al., “Prognostic Impact of Types of Atrial Fibrillation in Acute Coronary Syndromes,” American Journal of Cardiology, Vol. 104, No. 10, 2009, pp. 1317-1323. doi:10.1016/j.amjcard.2009.06.055
[31] V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, et al., “ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Circulation, Vol. 114, 2006, pp. e257-e354. doi:10.1161/CIRCULATIONAHA.106.177292
[32] K. A. Fox, T. C. Clayton, P. Damman, et al., “Long-Term Outcome of a Routine versus Selective Invasive Strategy in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome a Meta-Analysis of Individual Patient Data,” Journal of the American College of Cardiology, Vol. 55, No. 22, 2010, pp. 2435-2445. doi:10.1016/j.jacc.2010.03.007
[33] E. J. Benjamin, P. A. Wolf, R. B. D’Agostino, et al., “Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study,” Circulation, Vol. 98, 1998, pp. 946-952. doi:10.1161/01.CIR.98.10.946
[34] A. N. Mather, T. A. Fairbairn, N. J. Artis, et al., “Relationship of Cardiac Biomarkers and Reversible and Irreversible Myocardial Injury Following Acute Myocardial Infarction as Determined by Cardiovascular Magnetic Resonance,” International Journal of Cardiology, 2011. doi:10.1016/j.ijcard.2011.11.004
[35] I. Müller II, K. A. L. Müller, H. Sch?nleber, et al., “Macrophage Migration Inhibitory Factor Is Enhanced in Acute Coronary Syndromes and Is Associated with the Inflammatory Response,” PLoS ONE, Vol. 7, No. 6, 2012, Article ID: e38376. doi:10.1371/journal.pone.0038376
[36] E. Watanabe, T. Arakawa, T. Uchiyama, et al., “High-Sensitivity C-Reactive Protein Is Predictive of Successful Cardioversion for Atrial Fibrillation and Maintenance of Sinus Rhythm after Conversion,” International Journal of Cardiology, Vol. 108, No. 3, 2006, pp. 346-353. doi:10.1016/j.ijcard.2005.05.021
[37] A. S. Antonopoulos, M. Margaritis, R. Lee, et al., “Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials,” Current Pharmaceutical Design, Vol. 18, No. 11, 2012, pp. 1519-1530. doi:10.2174/138161212799504803
[38] G. Ramani, M. Zahid, C. B. Good, et al., “Comparison of Frequency of New-Onset Atrial Fibrillation or Flutter in Patients on Statins versus Not on Statins Presenting with Suspected Acute Coronary Syndrome,” American Journal of Cardiology, Vol. 100, No. 3, 2007, pp. 404-405. doi:10.1016/j.amjcard.2007.03.034
[39] M. Ozaydin, Y. Turker, D. Erdogan, et al., “The Association between Previous Statin Use and Development of Atrial Fibrillation in Patients Presenting with Acute Coronary Syndrome,” International Journal of Cardiology, Vol. 141, No. 2, 2010, pp. 147-150. doi:10.1016/j.ijcard.2008.11.172
[40] M. D. Miedema, C. A. Conover, H. MacDonald, et al., “Pregnancy-Associated Plasma Protein-A Elevation in Patients with Acute Coronary Syndrome and Subsequent Atorvastatin Therapy,” American Journal of Cardiology, Vol. 101, No. 1, 2008, pp. 35-39. doi:10.1016/j.amjcard.2007.07.045
[41] D. Al Khdair, L. Alshengeiti, B. Elbarouni, et al. (Global Registry of Acute Coronary Events (GRACE/GRACE2) and Canadian Registry of Coronary Events (CANRACE) Investigators), “Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation,” Canadian Journal of Cardiology, Vol. 28, No. 4, 2012, pp. 443-449. doi:10.1016/j.cjca.2011.12.011

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.